LLY241220P785000
- 20.00
- -3.48-14.82%
Eli Lilly and Co Newsroom
Express News | FDA: As of Dec 19, Dulaglutide Injection, Semaglutide Injection & Liraglutide Injection Are in Shortage
Hims & Hers Health Falls as FDA Issues Unfavorable Compounded GLP-1 Decision
Express News | FDA: Does Not Intend to Take Action Against Compounders for Violations of FD&C Act Arising From Conditions That Depend on Tirzepatide Injection
Express News | US FDA: Eli Lilly's Tirzepatide Injection Shortage Is Resolved as of Dec 19 - Website
Healthcare Stocks Had a Dismal Year. Therein Lies -2-
Trump's tariff plan is unpopular! More than half of the USA population opposes imposing taxes on commodities from Mexico.
①The plan of the USA's incoming president Trump to impose tariffs does not seem to be popular among the public. According to a poll, 51% of USA voters oppose imposing tariffs on commodities from Mexico, Canada, and China; ②Standard & Poor's states that USA tariffs will increase inflation rates and reduce economic output, while some citizens and businesses are stockpiling goods due to tariff concerns, leading to a significant increase in throughput at the ports of Los Angeles and Long Beach in November.
Hong Kong stocks movement | LAEKNA-B (02105) rose over 13% during the session as the company accelerates the clinical research and development of LAE102. It previously announced a partnership with Eli Lilly and Co in the USA.
LAEKNA-B (02105) rose over 13% during the session, and as of the time of writing, it is up 8.46%, priced at 10.38 Hong Kong dollars, with a trading volume of 72.4164 million Hong Kong dollars.
Tesla, Bitcoin, S&P 500, Dow, Tank: Thanks a Lot FOMC | Wall Street Today
Express News | FOMC Cuts Interest Rates by 25 Basis Points, Sees Fewer Reductions Next Year
Who's Next To Join Tesla, Broadcom In $1 Trillion Club? Over 50% Say The World's Biggest Retailer
10 Health Care Stocks With Whale Alerts In Today's Session
Vikings Therapeutics Plummets 11% As Merck Licenses a Weight-Loss Pill From A Chinese Drugmaker
Dow Breaks Downward Spiral, with FOMC Rate Cut on Deck | Live Stock
Merck-Hansoh Deal for Oral GLP-1 Hurts Obesity Drug Developers
Least Shorted S&P 500 Stocks in November
Lilly Rival Gets FDA Okay for Phase 2 Study of Obesity Drug
Express News | FDA Clears Gan & Lee's Investigational New Drug Application To Conduct Phase 2 Head-To-Head Trial Of Bi-Weekly Bofanglutide, For Chronic Weight Management Indication Against Eli Lilly's Tirzepatide
Eli Lilly's Kisunla Approved for Early Alzheimer's Patients in China
Eli Lilly Secures Chinese Approval for Early Symptomatic Alzheimer's Disease Medicine
Eli Lilly and Co's potential blockbuster new drug donanemab has been approved for sale in China! It is used for treating Alzheimer's disease.
On December 18, Eli Lilly and Co (LLY.US) just announced that its Class 1 new drug donanemab injection application has been approved by the National Medical Products Administration of China (NMPA).